研究者データベース


フリーワードで探す

全文検索となっています

志賀 一慶シガ カズヨシ

所属部署医学研究科消化器外科学分野
職名助教
メールアドレス
ホームページURL
生年月日
Last Updated :2020/05/14

研究者基本情報

学位

  • 医学博士, 名古屋市立大学大学院医学研究科

研究活動情報

研究キーワード

    サイトカイン, 癌-間質相互作用, 炎症性腸疾患, 下部消化管

論文

  • Apigenin induces apoptosis by suppressing Bcl-xl and Mcl-1 simultaneously via signal transducer and activator of transcription 3 signaling in colon cancer., Maeda Y, Takahashi H, Nakai N, Yanagita T, Ando N, Okubo T, Saito K, Shiga K, Hirokawa T, Hara M, Ishiguro H, Matsuo Y, Takiguchi S, International journal of oncology,   2018年03月, 査読有り
  • High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab, Masayasu Hara, Takaya Nagasaki, Kazuyoshi Shiga, Hiroki Takahashi, Hiromitsu Takeyama, SURGERY TODAY, 47, (4) 483 - 489,   2017年04月, 査読有り, We evaluated the relationship of the pretreatment serum IL-6 levels with the outcome and treatment response in patients with advanced or metastatic colorectal cancer (CRC) who underwent bevacizumab-containing chemotherapy. In this retrospective study, the pretreatment serum IL-6 and plasma vascular endothelial growth factor (VEGF) levels were measured in 113 patients with metastatic CRC. The cut-off values for these measurements, as determined by a receiver operating characteristic curve analysis, were 4.3 and 66 pg/mL, respectively. The median follow-up period was 19 months (range 1-40 months). Sixty-three patients had primary cancer, and 38 had a metachronous recurrence. Thirty patients underwent curative resection, and 71 underwent chemotherapy, 53 of whom received bevacizumab-containing chemotherapy. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier and multivariate Cox proportional hazards regression analyses. The plasma VEGF levels and positive KRAS mutation status were not associated with the outcomes. However, high serum IL-6 levels were significantly associated with poorer OS and PFS in comparison to low serum IL-6 levels. A Cox proportional hazards regression analysis showed that high serum IL-6 levels were an independent risk factor for a poor outcome. In patients with metastatic CRC, high pretreatment serum IL-6 levels were associated with a poor outcome and bevacizumab resistance.
  • Factors that predict the occurrence of and recovery from non-alcoholic fatty liver disease after pancreatoduodenectomy, Takafumi Sato, Yoichi Matsuo, Kazuyoshi Shiga, Mamoru Morimoto, Hirotaka Miyai, Hiromitsu Takeyama, SURGERY, 160, (2) 318 - 330,   2016年08月, 査読有り, Background. The manifestations of non-alcoholic fatty liver disease in patients who have undergone pancreatoduodenectomy differ from those associated with obesity-related non-alcoholic fatty liver disease. This study aimed to identify factors that predicted the occurrence of and recovery from non-alcoholic fatty liver disease after pancreatoduodenectomy. Methods. This retrospective study included 120 patients who underwent pancreatoduodenectomy between April 2004 and December 2013. Non-alcoholic fatty liver disease was diagnosed using unenhanced computed tomography as a value of <40 Hounsfield units. Recovery from non-alcoholic fatty liver disease was based on increases in liver computed tomographic attenuation values. Pre-, intra-, and postoperative factors were analyzed using univariate analysis and multivariable logistic regression models. Results. Non-alcoholic fatty liver disease occurred after pancreatoduodenectomy in 45 patients (38%), and in 11 of 41 patients (27%) who received prophylactic pancreatic enzyme supplementation therapy and in 34 of 79 patients (43 %) who did not (P =.082). Six patients received therapeutic supplementation after diagnosis. The non-alcoholic fatty liver disease recovery rates in patients who did and did not receive pancreatic enzyme supplementation therapy were 100% and 58%, respectively (P =.069). Multivariable analysis identified a high body mass index, small pancreatic volume, long operative time, and a high aspartate aminotransferase/alanine aminotransferase ratio 1 month after pancreatoduodenectomy as independent risk factors. A small diameter main pancreatic duct, a low serum amylase level at postoperative day 28, and a high minimum liver computed tomographic value predicted recovery from non-alcoholic fatty liver disease. Conclusion. The non-alcoholic fatty liver disease occurrence rate in patients undergoing pancreatoduodenectomy is high, but in about half of these patients, non-alcoholic fatty liver disease will resolve without any enzyme supplementation. Prophylactic supplementation in the postoperative management of pancreatoduodenectomy patients should be based on risk factors, and therapeutic supplementation should be based on recovery factors.
  • Suppression of Cancer-associated Fibroblasts and Endothelial Cells by Itraconazole in Bevacizumab-resistant Gastrointestinal Cancer, Masayasu Hara, Takaya Nagasaki, Kazuyoshi Shiga, Hiromitsu Takeyama, ANTICANCER RESEARCH, 36, (1) 169 - 177,   2016年01月, 査読有り, Background: We evaluated the ability of itraconazole to enhance the effects of bevacizumab in bevacizumab-resistant cancer cells, endothelial cells, and cancer-associated fibroblasts (CAFs). Materials and Methods: Human gastrointestinal cancer cell lines (HT-29, MKN-28 and MKN-45), human umbilical vein endothelial cells (HUVECs), and CAFs established from human colon cancer were used. In each of these cell lines, cell growth, apoptosis, and angiogenesis were evaluated with bevacizumab with and without itraconazole both in vitro and in vivo. Results: Itraconazole suppressed HUVEC growth by apoptosis through inhibition of mitogen-activated protein kinase and ribosomal protein S6 kinase signaling. Itraconazole also suppressed monocyte chemoattractant protein-1 secretion and the growth of CAFs. In xenografts, compared to monotherapy with either agent alone, combined treatment with itraconazole and bevacizumab significantly reduced tumor volume, tumor weight, and microvessel density. Conclusion: Itraconazole-dependent suppression of endothelial cell and CAF growth resulted in synergistic effects with bevacizumab in bevacizumab-resistant cancer cells.
  • Preoperative Serum Interleukin-6 Is a Potential Prognostic Factor for Colorectal Cancer, including Stage II Patients, Kazuyoshi Shiga, Masayasu Hara, Takaya Nagasaki, Takafumi Sato, Hiroki Takahashi, Mikinori Sato, Hiromitsu Takeyama, GASTROENTEROLOGY RESEARCH AND PRACTICE, 2016,   2016年, 査読有り, Aims. To evaluate the prognostic significance of serum interleukin-6 (IL-6) in colorectal cancer (CRC). Patients and Methods. Preoperative serum IL-6 was measured in 233 CRC patients and 13 healthy controls. Relationships between IL-6 and various clinicopathological factors were evaluated, and the overall survival (OS) and disease-free survival (DFS) rates according to IL-6 status were calculated for all patients and according to disease stage. Results. The mean IL-6 level was 6.6pg/mL in CRC patients and 2.6 pg/mL in healthy controls. Using a cutoff of 6.3 pg/mL, obtained using receiver operating characteristic curve analysis, 57 patients had a high IL-6 level. The mean value was higher for stage II disease than for stage III disease. IL-6 status correlated with C-reactive protein (CRP) and carcinoembryonic antigen levels, obstruction, and pT4 disease. The OS differed according to the IL-6 status for all patients, whereas the DFS differed for all patients and for those with stage II disease. The Cox proportional hazards model showed that pT4 disease was an independent risk factor for recurrence in all CRC patients; IL-6, CRP, and pT4 were significant risk factors in stage II patients. Conclusions. The preoperative IL-6 level influences the risk of CRC recurrence.
  • Laparoscopic resection of retroperitoneal lymphangioma around the pancreas: a case report and review of the literature., Sato T, Matsuo Y, Shiga K, Saito K, Morimoto M, Miyai H, Takeyama H, Journal of medical case reports, 9,   2015年12月, 査読有り
  • Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth., Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H, Cancers, 7, (4) 2443 - 2458,   2015年12月, 査読有り


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.